Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Post by JAKPUG4LIFEon Apr 06, 2023 3:50pm
123 Views
Post# 35383761

Facts and Financials Matter

Facts and Financials Matter
Post by GrahamBon Apr 02, 2023 11:28am
97 Views 
Post# 35374537

Financials First Pass

Hi all,
Not here much, and just read the financials.

Key highlights for me:

"As at December 31 2022, the Company had cash and cash equivalents of $16,980,472 representing a decrease of $18,279,173 from December 31, 2021. This decrease is primarily due to $28,333,273 of cash used in operating activities, $12,123,408 of cash provided by investing activities and $2,069,308 of cash used in financing activities." Source SEDAR.com
 
 
So we read that Cash and cash equivalents 
16,980,472 
And a decrease of (18,279,173) or  -52%
 
So it looks like, IMO, a cash raise, and dilution will be required, if the cash burn is 18 m illion /year and this is BEFORE the more costly phase 1/2 trials have started 
This raised the question Why they were buying back stock?
Hmmmmm
Lets see?
Any thoughts?

Is that loud flushing sound the further dilution coming?
all IMO, do your own DD

<< Previous
Bullboard Posts
Next >>